Affymax and Takeda Pharmaceutical's drug candidate peginesitide was accepted for FDA review. Formerly named Hematide, the once-monthly drug is intended for anemia in kidney patients on dialysis.
Published in Brief:
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore